About the Practice
He was the lead author on the study that established lecanemab as the first disease-modifying treatment for Alzheimer’s disease. Predictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease.
Category
ADHDAging/ElderlyChildhood TraumaDepressionGender IdentityGriefLGBTQ+Sexual Abuse
Insurance Accepted
EmblemHealth
Is this your practice?
Claim your free profile today
Update your info, respond to reviews, and connect with new clients.
Claim This Profile